SciClone Pharmaceuticals to Report 2012 Financial Results and 2013 Outlook on April 1st

SciClone Pharmaceuticals to Report 2012 Financial Results and 2013 Outlook on 
April 1st 
FOSTER CITY, CA -- (Marketwire) -- 04/01/13 --  SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to
report 2012 financial results and 2013 outlook today, Monday, April
1, 2013. SciClone will host a conference call and webcast to provide
a business and product update at 4:30 pm ET today. The call will be
hosted by Friedhelm Blobel, Ph.D., President and CEO, and Gary Titus,
Senior Vice President and CFO. 
 877 299 4454 (U.S./Canada)
 617 597 5447 (International) 
Passcode: 11945575 
 888 286 8010 (U.S./Canada)
 617 801 6888
 Passcode: 95860527 
 (Replay available from Monday,
April 1, 2013, at 6:30 pm ET until 11:59 pm ET on Monday, April 8,
The conference call will contain forward-looking statements.
Interested parties who wish to listen to the webcast should visit the
Investor Relations section of SciClone's website at
The information provided on the teleconference is accurate only at
the time of the conference call, and SciClone will take no
responsibility for providing updated information except as required
by law.  
About SciClone  
SciClone Pharmaceuticals is a US-based, 
China-focused specialty
pharmaceutical company with a product portfolio of therapies for
oncology, infectious diseases and cardiovascular, urological,
respiratory, and central nervous system disorders. SciClone's
ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Besides ZADAXIN, SciClone markets about 14
mostly partnered products in China, including Depakine(R), the most
widely prescribed broad-spectrum anti-convulsant in China;
Tritace(R), an ACE inhibitor for the treatment of hypertension;
Stilnox(R), a leading hypnotic for the short-term treatment of
insomnia (marketed as Ambien(R) in the US); and Aggrastat(R), a
recently-launched interventional cardiology product. SciClone is also
pursuing the registration of several other therapeutic products in
China. SciClone is headquartered in Foster City, California. For
additional information, please visit  
Forward-Looking Statements This press release contains
forward-looking statements regarding expected financial results and
expectations. Readers are urged to consider statements that include
the words "may," "will," "would," "could," "should," "might,"
"believes," "estimates," "projects," "potential," "expects," "plans,"
"anticipates," "intends," "continues," "forecast," "designed,"
"goal," "unaudited," "approximately" or the negative of those words
or other comparable words to be uncertain and forward-looking. These
statements are subject to risks and uncertainties that are difficult
to predict and actual outcomes may differ materially. These include
risks and uncertainties relating to: changes in results that may
occur in completing the close of SciClone's consolidated financial
statements for fiscal year 2012 and completing the audit of
SciClone's consolidated financial statements for fiscal year 2012;
the course, cost and outcome of regulatory matters; the Company's
ability to execute on its goals in China and on its objectives for
revenue in fiscal 2013; the challenges presented by integrating an
acquired business into existing operations; the variability in
earnings on a GAAP basis that may result from non-cash charges
related to the NovaMed acquisition; the dependence on third-party
license, promotion or distribution agreements including the need to
renew such agreements; operating an international business; the
clinical trial process, including the regulatory approval and the
process of initiating trials at, and enrolling patients at, clinical
sites; the effect of changes in its practices and policies related to
the Company's compliance programs and SciClone's ability to attract
and retain key personnel. SciClone cannot predict the timing or
outcome of the SEC and DOJ investigations, or of the level of its
efforts required to cooperate with those investigations, however the
Company has incurred substantial expenses in connection with the
investigations and related litigation and expects to incur additional
expense and the investigations could result in fines and further
changes in its internal control or other remediation measures that
could adversely affect its business. Please also refer to other risks
and uncertainties described in SciClone's filings with the SEC. All
forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements. 
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC in numerous other countries. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
Corporate Contacts 
Gary Titus
Chief Financial Officer
Jane Green
Press spacebar to pause and continue. Press esc to stop.